tiprankstipranks
Trending News
More News >
Vera Therapeutics (VERA)
NASDAQ:VERA
US Market

Vera Therapeutics (VERA) AI Stock Analysis

Compare
703 Followers

Top Page

VE

Vera Therapeutics

(NASDAQ:VERA)

Rating:39Underperform
Price Target:
Vera Therapeutics' overall stock score is driven by ongoing financial challenges, including consistent losses and negative cash flows, despite a strong equity position. Technical analysis indicates bearish momentum, with the stock underperforming key moving averages. The valuation is unattractive due to a negative P/E ratio and no dividend yield.
Positive Factors
Clinical Efficacy
Atacicept demonstrated a statistically significant 42% reduction in urine protein creatinine ratio compared to placebo, providing convincing evidence to support its best-in-class potential.
Market Opportunity
The IgAN market is considered large enough to support multiple products, offering growth potential for Vera Therapeutics.
Safety Profile
Safety appears clean for both atacicept and sibeprenlimab, which is favorable for market acceptance.
Negative Factors
Competitive Position
There will be pressure on VERA shares as there are increased questions regarding atacicept’s position in the evolving IgAN landscape.
Data Methodology Uncertainty
Uncertainty exists about whether Vera and Otsuka used the same statistical methodology and imputation of missing data in their respective analyses.
Market Reaction
The market price of VERA reacted negatively, with the stock declining ~30% after Otsuka presented data from its Phase 3 VISIONARY study.

Vera Therapeutics (VERA) vs. SPDR S&P 500 ETF (SPY)

Vera Therapeutics Business Overview & Revenue Model

Company DescriptionVera Therapeutics (VERA) is a biotechnology company focused on developing transformative treatments for serious immunological diseases. With a strong emphasis on research and development, the company's core product pipeline includes innovative therapies aimed at addressing unmet needs in the treatment of kidney diseases and other immune-related conditions.
How the Company Makes MoneyVera Therapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. The company's revenue model includes licensing agreements, research collaborations, and eventually, sales of approved therapies. Key revenue streams involve upfront payments, milestone payments, and royalties from commercial partnerships with larger pharmaceutical companies. Significant partnerships with industry leaders and research organizations play a crucial role in advancing their drug development programs and contributing to potential future earnings.

Vera Therapeutics Financial Statement Overview

Summary
Vera Therapeutics faces financial instability with consistent net losses and negative EBIT margins. Although there is a positive trend in gross profit, cash flow challenges remain due to negative free cash flows and reliance on financing. The balance sheet shows a strong equity position with low debt leverage, but fluctuations in the equity ratio indicate potential asset management volatility.
Income Statement
25
Negative
Vera Therapeutics has faced a challenging period with consistent net losses and negative EBIT margins over the years. The absence of revenue growth and a significant increase in net losses highlight financial instability. However, the improvements in gross profit from negative to positive values in recent years offer a slight positive trajectory.
Balance Sheet
55
Neutral
The company demonstrates a strong equity position with a growing stockholders' equity, minimizing debt leverage. The debt-to-equity ratio remains low, indicating prudent financial management. However, the overall equity ratio has fluctuated, reflecting potential volatility in asset management.
Cash Flow
40
Negative
Vera Therapeutics experiences negative free cash flows, with operating cash flow consistently below net income, highlighting cash management challenges. A positive note is the significant financing inflows that bolster cash reserves, although relying on financing isn't sustainable long-term.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.001.86M0.000.000.00
Gross Profit0.000.001.86M846.00K-176.00K-251.00K
EBITDA-175.16M-167.17M-102.01M-90.90M-34.23M-52.99M
Net Income-175.46M-152.15M-95.99M-89.06M-32.61M-53.41M
Balance Sheet
Total Assets610.17M655.68M175.55M131.44M83.75M54.55M
Cash, Cash Equivalents and Short-Term Investments589.83M640.85M160.72M114.65M79.67M53.65M
Total Debt54.47M54.64M53.71M31.29M4.92M2.00K
Total Liabilities75.17M78.53M73.86M54.53M14.16M143.90M
Stockholders Equity535.00M577.15M101.69M76.91M69.59M-89.35M
Cash Flow
Free Cash Flow-156.41M-135.65M-92.24M-67.66M-23.71M-34.91M
Operating Cash Flow-155.25M-134.68M-92.18M-67.60M-23.71M-34.81M
Investing Cash Flow-190.43M-425.03M-39.43M-70.55M-4.20M-42.00K
Financing Cash Flow331.67M606.67M133.54M101.93M53.88M85.29M

Vera Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price22.97
Price Trends
50DMA
22.84
Positive
100DMA
24.45
Negative
200DMA
33.33
Negative
Market Momentum
MACD
0.08
Negative
RSI
50.06
Neutral
STOCH
48.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VERA, the sentiment is Negative. The current price of 22.97 is above the 20-day moving average (MA) of 22.53, above the 50-day MA of 22.84, and below the 200-day MA of 33.33, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 50.06 is Neutral, neither overbought nor oversold. The STOCH value of 48.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VERA.

Vera Therapeutics Risk Analysis

Vera Therapeutics disclosed 85 risk factors in its most recent earnings report. Vera Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Vera Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
$3.07B-32.17%-25.85%-23.89%
58
Neutral
$1.63B-5.78%25.50%64.63%
55
Neutral
$2.18B-31.51%
52
Neutral
$7.45B0.27-61.87%2.30%16.62%1.04%
51
Neutral
$1.30B-422.66%49.29%44.52%
43
Neutral
$1.85B-23.34%-14.19%
39
Underperform
$1.46B-39.49%-20.03%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
VERA
Vera Therapeutics
23.00
-12.06
-34.40%
TVTX
Travere Therapeutics
15.30
5.81
61.22%
IRON
Disc Medicine
52.97
6.00
12.77%
KYMR
Kymera Therapeutics
43.43
3.99
10.12%
IMCR
Immunocore Holdings
33.28
-5.01
-13.08%
NAMS
NewAmsterdam Pharma Company
20.02
0.02
0.10%

Vera Therapeutics Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Vera Therapeutics Highlights Atacicept Progress at Conference
Positive
Jan 13, 2025

Vera Therapeutics announced an updated corporate presentation at the J.P. Morgan Healthcare Conference, highlighting the progress of their lead therapy, atacicept, in clinical trials. The company is positioned strongly with $677 million in cash and marketable securities, and is focused on potential commercial launch plans, bolstered by breakthrough therapy designation from the FDA for atacicept in treating IgAN. The company aims to expand atacicept’s indications to other autoimmune and kidney diseases, with several clinical trials underway.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 21, 2025